Skip to content

Released Aug 12, 2021, after the close

10-Q filed Aug 12, 2021, 43 days after period end · 0001390478-21-000030

Q2 2021 · 10-Q
Revenue$1.90M— vs Q2 2020−66.7% vs Q1 2021
Net Income-$4.61MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.30N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$4,453,000N/M
Operating Cash Flowderived-$4,898,000N/M
Margins · derived
Operating margin-234.4%
Net margin-242.8%

What the release said

The release

Same quarter

MetricQ2 2021Q2 2020Q2 2019Q2 2018
Revenue$1.90M$0.00——
Net Income-$4.61M-$4.43M-$3.13M-$6.06M
EPS Diluted-$0.30-$0.66-$6.33-$1.26

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR